เอกสารอ้างอิง
1.National Comprehensive Cancer Network. Antiemesis (Version 3.2018).[cited July 26,2020].Available from: URL:http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf
2.United States Food and Drug Administration. Zofran (ondansetron): Drug safety communicationupdated information on 32 mg intravenous ondansetron (Zofran) dose and pre-mixed ondansetron products [online].2012. [cited July 26,2020 ]. Available form: www.fda.gov/drugs/ drugsafety/ucm330049.htm
3. Micromedex® [Database on internet]. Colorado: Thomson Reuters (Healthcare). Available from: http://www.micromedexsolutions.com /micromedex2/librarian/.
4.Taylor S.Zofran (ondansetron)-dosage and administration of intravenous ondansetron in geriatrics (>65 years of age)-for health professionals [online]. 2014 [cited July 26,2020]. Available form: www. healthycanadians.gc.ca/recall-alert-rappel-avis/hcsc/2014/39943a-eng.php.
5.Casper J, Casper S, Kohnewompner C, Bokemeyer C, Hecker H, Schmoll H. 5-HT-3 antagonist ondansetron for the treatment of chemotherapy-induced nausea and vomiting in an outpatient population.Int J Oncol.1994. วันที่ตอบ : 01 ธ.ค. 63 - 10:41:22